Role of Cox2 Inhibitors Used in The Treatment of Breast Cancer: An Overview

Abstract

Breast cancer is a disease that is both common and complex, requiring novel therapeutic methods due to its varied genetic subtypes. The changing role of cyclooxygenase-2 (COX-2) inhibitors in the management of breast cancer is explored in this study. This article examines the molecular foundation of COX-2 participation in breast cancer and clarifies the processes by which COX-2 inhibitors exercise their anti-cancer effects. COX-2 has been linked to inflammation and the growth of cancer. The study critically assesses the present status of clinical research, covering both encouraging results and difficulties related to the use of COX-2 inhibitors in the treatment of breast cancer. The future direction of this research is highlighted, highlighting the need for refined treatment regimens and well-controlled clinical trials to establish the true efficacy and safety profile of COX-2 inhibitors in breast cancer therapy, as we navigate the complexities of patient selection, optimal dosages, and potential side effects. In the end, this review seeks to offer a thorough summary of the current situation and potential future applications of COX-2 inhibitors in the management of breast cancer.

Keywords

Introduction

We also explore the mechanisms via which COX-2 inhibitors work against cancer disease, offering a summary of the state of clinical research at the moment. We examine the potential benefits and drawbacks of using COX-2 inhibitors in the treatment of breast cancer by critically evaluating the body of current research. ^[5]

Here are some potential benefits and considerations:

1. COX-2 inhibitors are predominantly recognized for their anti-inflammatory characteristics. Reducing inflammation may potentially help cancer patients as it contributes to the onset and spread of the disease. Research is still ongoing to determine how precisely COX-2 inhibitors affect inflammation in breast cancer, though.
2. Inhibition of Angiogenesis: The ability of COX-2 inhibitors to prevent angiogenesis, the process by which tumors create new blood vessels to sustain their growth, has been investigated. COX-2 drugs may delay the growth of tumors by interfering with this mechanism.

3. Adjunct Therapy: COX-2 inhibitors aren't usually used to treat breast cancer on their own. Rather, they can be used in conjunction with other treatments like as hormone therapy or chemotherapy, as they are regarded as adjunct therapies. Research has looked into whether adding COX-2 inhibitors to conventional breast cancer treatments dewill enhance results or lessen side effects.
4. Pain Management: COX-2 inhibitors may be used in certain situations to treat or alleviate pain related to breast cancer. They may be recommended, for instance, to treat joint discomfort brought on by specific drugs.
5. Chemo-Sensitization: According to some study, COX-2 inhibitors may increase the sensitivity of cancer cells to chemotherapy medications, hence improving the efficacy of chemotherapy treatment. To validate this effect and identify the most effective ways to combine these treatments, more research is necessary.
6. Hormone Receptor Status: Depending on whether the breast cancer has hormone receptors or not, COX-2 inhibitors may or may not be beneficial. For instance, they may work better on breast tumors that do not bind to hormone receptors than on those that do.

Drawbacks of COX 2 Inhibitor for breast cancer:

1. Cardiovascular Risks: One of the main negative effects of COX-2 inhibitors is that they may make cardiovascular events like heart attacks and stroke more likely. This danger was especially noticeable with some COX-2 inhibitors, such as Vioxx (rofecoxib), which was taken off the market because of safety concerns. Even though the cardiovascular risk profile of more recent COX-2 inhibitors may be decreased, this is still something to take into account, particularly for individuals who already have cardiovascular disease.
2. COX-2 inhibitors may result in gastrointestinal adverse effects, including bleeding, perforation, and stomach ulcers. These dangers are still there, but they are less than those associated with non-selective NSAIDs (non-steroidal anti-inflammatory medicines). Individuals who have experienced gastrointestinal problems in the past or who are taking other drugs that raise the risk of GI hemorrhage should be strictly watched if COX-2 inhibitors are administered.

We emphasize that, as the field develops, it will be crucial to fine-tune treatment plans, find predictive biomarkers, and carry out carefully supervised clinical studies in order to determine the actual potential of COX-2 inhibitors in improving the field of breast cancer therapy.^[6] The successful translation of preclinical information about the potential efficacy of COX-2 inhibitors in breast cancer remains a complicated task, despite the strong evidence.^[4] There are continuous discussions in the scientific and medical communities regarding the necessity for precise patient selection criteria, worries about side effects, and contradictory outcomes from clinical studies.

II. Pathogenesis of breast cancer by COX 2 molecule:

An essential component of the arachidonic acid metabolic pathway, the enzyme cyclooxygenase-2 (COX-2) has been linked to a number of physiological functions, including tissue homeostasis, inflammation, and the immune system. On the other hand, it has become clear that deregulation of COX-2 expression and activity plays a major role in the advancement of breast cancer.

The key steps in the deregulation of COX-2 expression are :

Cellular stress triggers the activation of various transcription factors, such as NF-κB, AP-1, and CREB.

The activated transcription factors bind to the COX-2 gene promoter, leading to increased transcription of the COX-2 gene.

The increased COX-2 mRNA is then translated into COX-2 protein.

The COX-2 protein becomes enzymatically active, leading to increased synthesis of prostaglandins.

The elevated prostaglandin levels contribute to inflammation, angiogenesis, and cell proliferation, which are hallmarks of various pathological conditions, such as cancer, arthritis, and cardiovascular diseases.

This flowchart provides a simplified overview of the key steps involved in the deregulation of COX-2 expression, which is an important process in the pathogenesis of various diseases.

COX-2's complicated molecular basis in breast cancer is mediated by a complex interaction of genetic changes, signaling pathways, and environmental variables.

1. Prostaglandin Production: ^[8]

Breast cancer is associated with COX-2 overexpression. COX-2 catalyzes the conversion of arachidonic acid into prostaglandins, which are powerful inflammatory mediators and modulators of numerous biological processes. Overexpression of COX-2 in breast cancer results in increased prostaglandin production, especially in prostaglandin E2 (PGE2). Increased angiogenesis, decreased apoptosis, and enhanced tumor cell invasion and migration have all been linked to elevated PGE2 levels.

2.Microenvironment of Inflammation:

Reciprocal Interaction: There is ample evidence linking inflammation to cancer, and COX-2 is essential for promoting an inflammatory milieu in breast tissue. The activation of pro-survival signaling pathways, DNA damage, and genetic instability are all influenced by chronic inflammation. In addition to maintaining an environment that is conducive to tumor growth, COX-2-mediated inflammation also encourages resistance to anti-cancer treatments.

3.Angiogenesis and the Development of Tumors:

Angiogenic Factors: Angiogenesis induction, a crucial step in the development of tumors, has been linked to COX-2. One important mediator of angiogenesis, vascular endothelial growth factor (VEGF), is upregulated in response to prostaglandins generated by COX-2. A sufficient blood supply to the expanding tumor is guaranteed by enhanced angiogenesis, which promotes the tumor's survival and propensity for metastasis.

4.Proliferation and Survival of Cells:

Cell Cycle Regulation: By affecting the course of the cell cycle, COX-2 encourages the growth of cells. It contributes to unchecked cell proliferation through modulating cyclins, cell cycle inhibitors, and cyclin-dependent kinases (CDKs). Furthermore, anti-apoptotic processes are promoted by COX-2-mediated signaling pathways, which increases the viability of cancer cells.

5.Mesenchymal-to-epithelial transition (EMT):

Metastasis and Invasion: The process of epithelial-mesenchymal transition (EMT), which is essential for the spread of cancer, has been associated with COX-2. Cancer cells can become more invasive through EMT, which makes it easier for them to spread to distant organs. Increased motility, invasiveness, and resistance to apoptosis are linked to COX-2-driven EMT.

6.Control of Hormones:

[9] Interaction with Hormones: The development of breast cancer is closely linked to hormonal regulation, and hormonal factors have an impact on the expression of COX-2. A crucial hormone in breast cancer, estrogen, has the ability to increase COX-2 expression, which feeds back positively and accelerates the growth of tumors.  

Breast cancer is closely linked to hormonal regulation, particularly with estrogen and progesterone. The development and progression of many breast cancers are influenced by these hormones. Here’s a breakdown of how hormonal regulation is connected to breast cancer:

Breast cancers that are ER-positive: These tumors have estrogen receptors. Hormone therapy medications that inhibit the effects of estrogen or diminish its production are frequently used to treat them since they may be dependent on it for growth.

Hormone Therapy: Breast cancers that are hormone receptor-positive are frequently treated with hormone therapy. It seeks to prevent progesterone or estrogen from having an effect on cancer cells. Medication such as aromatase inhibitors (AIs), which lower the production of estrogen, tamoxifen, and other selective estrogen receptor modulators (SERMs) or pharmaceuticals that block both progesterone and estrogen receptors (fulve strant, for example) can accomplish this.

Hormonal Shifts and Menopause: The menopausal state may potentially impact the risk of breast cancer. Compared to premenopausal women, postmenopausal women have decreased levels of circulating estrogen. But some postmenopausal women continue to manufacture estrogen in other tissues (such adipose tissue), and this estrogen can fuel the development of breast tumors that are hormone receptor-positive.

Hormone Replacement Therapy (HRT): In postmenopausal women, the use of HRT, especially estrogen-progestin combinations, has been linked to an increased risk of breast cancer. This is due to the possibility that hormone-receptor-positive breast tumors could grow more quickly when more hormones are supplied by HRT.
Endocrine Disruptors: A class of compounds that mimic or tamper with the body's hormonal signals are referred to as endocrine disruptors. Extended exposure to these drugs may raise the risk of hormone-related malignancies, such as breast cancer, and contribute to hormonal imbalances.

III. COX-2 Inhibitors' Mechanisms of Action in Breast Cancer:

A class of medications known as cyclooxygenase-2 (COX-2) inhibitors, which have long been used for their anti-inflammatory effects, have drawn interest as possible breast cancer treatment options. Through a number of different mechanisms, including the targeting of important pathways implicated in angiogenesis, cancer growth, and resistance to apoptosis, COX-2 inhibitors have anti-cancer effects. In this section, we explore the specific ways by which COX-2 inhibitors function in relation to breast cancer. ^[10]

1.Prostaglandin Synthesis Inhibition:

The primary mechanism of action of COX-2 inhibitors is mostly associated with the reduction of prostaglandin production. These medications prevent arachidonic acid from being converted into prostaglandins, especially prostaglandin E2 (PGE2), by preventing the enzymatic activity of COX-2. Decreased PGE2 levels result in less inflammatory signaling and subsequent effects linked to the advancement of cancer. ^[11]

2.Counterproductive Impacts:

Cell Cycle Regulation: By altering the cell cycle, COX-2 inhibitors have anti-proliferative effects. They alter the expression of important regulators, including cell cycle inhibitors, cyclins, and cyclin-dependent kinases (CDKs). COX-2 inhibitors cause cell cycle arrest by interfering with the normal course of the cell cycle, which stops breast cancer cells from proliferating uncontrollably. ^[12]

3.Acquiring Apoptosis:

Pro-Apoptotic Signaling: Apoptosis is a mechanism of programmed cell death that is essential for preserving cellular homeostasis, and COX-2 inhibitors support it. These inhibitors work by affecting the pro- and anti-apoptotic signaling pathways. ^[13]

IV. Clinical Evidence of COX-2 Inhibitors in Breast Cancer:

 A body of clinical evidence has accompanied the investigation of cyclooxygenase-2 (COX-2) inhibitors in the treatment of breast cancer, but with mixed outcomes. Here, we dig into the specifics of the clinical evidence, going over important research and conclusions that have added to the continuing conversation over the safety and effectiveness of COX-2 inhibitors in relation to breast cancer.

1.Combining Celecoxib with Hormone Treatment:

Celecoxib, a COX-2 inhibitor, was used with hormone therapy in a randomized, double-blind, placebo-controlled trial involving postmenopausal women with hormone receptor-positive breast cancer. According to the study, progression-free survival was enhanced by the addition of celecoxib to hormone therapy as opposed to hormone therapy alone. Celecoxib-related cardiovascular events have drawn attention, too, emphasizing the importance of carefully weighing the advantages and disadvantages.

2.Adjuvant Celecoxib Usage:

Numerous investigations have looked into the adjuvant use of celecoxib in conjunction with conventional treatments for breast cancer. Some trials showed promise for increased survival and recurrence rate reductions, but others did not yield statistically significant gains. The intricacy of evaluating COX-2 inhibitors in the adjuvant context is highlighted by the variety in outcomes, which is a result of the variation in trial designs, patient groups, and treatment regimens.

3.Chemo preventive Prospects in Women at High Risk:

Mixed results have been found in trials examining the chemo preventive potential of COX-2 inhibitors in women at high risk of breast cancer. A study assessing celecoxib's effects in women with atypical hyperplasia or breast cancer history found that the incidence of contralateral breast cancer was lower. But scepticism over side effects, especially cardiovascular hazards, has dampened enthusiasm for routine COX-2 inhibitor usage in chemoprevention. ^[14,15]

4.Comparative Outcomes for Breast Cancer Spread: ^[2]

Results from clinical trials examining the use of COX-2 inhibitors in metastatic breast cancer have been inconsistent. Some studies reported no appreciable benefits, while others suggested possible benefits in terms of tumor response and progression-free survival. The variety of patient groups, past medical histories, and molecular subtypes could be a factor in the varying results seen in these trials.

5.Obstacles & Things to Think About:

The clinical evidence for COX-2 inhibitors in breast cancer is marked by difficulties in managing potential side effects, identifying the best patient demographics, and determining appropriate dosages. Particularly with regard to cardiovascular issues, caution has been exercised when using COX-2 inhibitors, highlighting the importance of customized risk-benefit analyses. ^[16]

V. Challenges and Future Directions in the Use of COX-2 Inhibitors in Breast Cancer: ^[17]

1.cardiovascular issues:

The possibility for cardiovascular side effects is one of the main issues with using COX-2 inhibitors. Concerns regarding an elevated risk of cardiovascular events, such as heart attacks and strokes, have been brought up by certain studies, especially when using certain COX-2 inhibitors over an extended period of time. In order to protect patients, it is imperative that these cardiovascular risks are addressed. Therefore, future studies should concentrate on devising ways to allay these worries, perhaps by identifying patient subgroups with reduced cardiovascular risk profiles.

2.Choosing Patients and Biomarkers:

The heterogeneity of breast cancer makes it difficult to pinpoint the patient groups that might benefit most from COX-2 inhibitor treatment. The identification and validation of biomarkers capable of accurately predicting a tumour’s sensitivity to COX-2 inhibitors ought to be the top priority for future research. To identify particular subtypes of breast cancer that are more receptive to the anti-cancer effects of COX-2 inhibition, molecular profiling may be necessary.

3.Ideal Course of Treatment:

It is a continuous task to identify the COX-2 inhibitor therapy regimens that are both most effective and well-tolerated. This entails investigating the right dosage, length of therapy, and possible combination treatments. Careful thought must go into combining COX-2 inhibitors with hormone therapy, targeted medicines, and chemotherapy standard treatments for breast cancer. Future studies should focus on improving treatment regimens through carefully planned clinical trials that take safety and efficacy into account. ^[18]

4.Getting Rid of Resistance Mechanisms:

In certain cases, COX-2 inhibitor resistance may restrict its efficacy. It is essential to comprehend the molecular mechanisms driving resistance in order to devise methods for getting around or beyond this restriction. Combination therapy with additional targeted drugs or the discovery of secondary targets within the COX-2 signaling pathway that can be used to increase the effectiveness of treatment are two possible approaches for this. ^[25]

5.Extended Safety and Adverse Reactions:

One important factor to keep in mind is the COX-2 inhibitors' long-term safety profile in patients with breast cancer. Long-term use raises concerns about the possibility for side consequences, including gastrointestinal problems, renal difficulties, and cardiovascular events, even though short-term studies may show efficacy. Comprehensive, long-term follow-up studies should be a part of future research to evaluate the safety and tolerability of COX-2 inhibitors in the context of treating breast cancer.

6.Methods in Personalized Medicine: In oncology, the era of personalized medicine places a strong emphasis on customizing treatments for each patient based on their own genetic and molecular traits. The creation of customized medicine strategies, in which patients are categorized according to particular biomarkers or genetic signatures that indicate responsiveness to COX-2 inhibition, should be a focus of future COX-2 inhibitor research. This strategy may optimize treatment gains while reducing dangers and needless exposure for patients who are not responding. ^[22]

7.Investigating Novel Inhibitors of COX-2:

The creation of new COX-2 inhibitors with enhanced selectivity, effectiveness, and safety profiles should be the subject of ongoing study. The development of inhibitors with a targeted specificity for cancer cells while preserving healthy tissues could reduce side effects and improve the therapeutic index. To improve drug delivery particularly to tumor locations, other delivery modalities including nanoparticle-based drug delivery systems should be investigated. ^[19]

8.Extensive, Strictly Managed Clinical Trials:

The need for extensive, carefully monitored clinical trials to determine the actual efficacy and safety of COX-2 inhibitors in breast cancer is highlighted by the inconsistent outcomes from earlier trials. These trials ought to take into account a range of patient demographics, distinct molecular subtypes of breast cancer, and different phases of the illness. Sturdy research designs such as randomized controlled trials are necessary to produce conclusive results and direct therapeutic practice.

CONCLUSION:

In conclusion, research into the function of COX-2 inhibitors in the management of breast cancer is an intriguing and complex field. First, there were great expectations for these inhibitors' clinical success because to their well-defined mechanisms of action and encouraging preclinical data demonstrating their anti-tumor properties. Nonetheless, difficulties and complexities have arisen when attempting to translate preclinical achievement into significant clinical effects. Conflicting outcomes from clinical trials investigating the use of COX-2 inhibitors in breast cancer have forced a critical reevaluation of their clinical usefulness. Issues about cardiovascular hazards linked to extended usage and the requirement for patient classification using particular molecular markers have emerged as essential elements of the current conversation. It is evident that adding COX-2 inhibitors to therapy regimens for breast cancer may not be appropriate when using a one-size-fits-all strategy. The potential advantages of COX-2 inhibition should not be overshadowed by the difficulties encountered during clinical studies. Subsequent investigations have to concentrate on surmounting these obstacles by honing in on patient selection standards, maximizing dosage schedules, and pinpointing prognostic indicators. The incorporation of COX-2 inhibitors into a tailored therapeutic regimen, wherein the most susceptible individuals are identified, has the potential to augment the general effectiveness and safety characteristics of these drugs. Furthermore, further research should be done on the investigation of COX-2 inhibitor combo treatments. A more effective and all-encompassing approach to the fight against breast cancer may be provided by combinatorial methods that combine the anti-cancer effects of COX-2 inhibitors with other targeted medicines or conventional treatments. This line of inquiry is consistent with the emerging concept of precision medicine, which designs customized therapeutic strategies according to the particulars of each patient's tumor. In summary, despite ongoing obstacles, research into the potential of COX-2 inhibitors for the treatment of breast cancer is still ongoing. In the complicated field of breast cancer, further research that is informed by a deeper comprehension of the molecular nuances involved will be necessary to fully realize the therapeutic potential of COX-2 inhibitors. The extensive knowledge gathered from preclinical and clinical research will surely impact the trajectory of COX-2 inhibitors as an important part of the toolkit against this challenging illness as we navigate the future of breast cancer therapies.

REFERENCES

1. Hanna Piotroska, BeataStanisz,Marek Murias,COX-2 inhibitors: a novel strategy in the management of breast cancer, Drug Discovery Today Volume 21, Issue 4, April 2016, Pages 598- 615.
2. Chow, L. W. C., Loo, W. T. Y., & Toi, M. (2005). Current directions for COX-2 inhibition in breast cancer. Biomedicine & Pharmacotherapy, 59, S281–S284.
3.  Mi?osz Regulski, Katarzyna Regulska, Wies?aw Pruka?a, Hanna Piotrowska, Beata Stanisz and Marek Murias. COX-2 inhibitors: a novel strategy in the management of breast cancer. Drug Discovery Today Volume 21, Number 4 April 2016.
4. Gargi D. Basu, Latha B. Pathangey, Teresa L. Tinder, Michelle LaGioia, Sandra J. Gendler, Pinku Mukherjee. Cyclooxygenase-2 Inhibitor Induces Apoptosis in Breast Cancer Cells in an In vivo Model of Spontaneous Metastatic Breast Cancer. Mol Cancer Res (2004) 2 (11): 632–642.
5. Demetrios Morisa Michalis Kontosa Eleftherios Spartalisa Ian S. Fentimanb, The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives, Breast Care 2016;11:339– 344.
6. Manon Cairat, Marie Al Rahmoun, Marc J. Gunter, Gianluca Severi, Laure Dossus and Agnès Fournier. Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women, Cairat et al. Breast Cancer Research (2020) 22:118.
7. Evrim Gurpinar , William E. Grizzle ,Gary A. Piazza. COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs. Front. Oncol., 11 July 2013 Sec. Cancer Molecular Targets and TherapeuticsVolume 3 – 2013.
8. IH Abdulkareem, IB Zurmi. Review of hormonal treatment of breast cancer. Nigerian Journal of Clinical Practice • Jan-Mar 2012 • Vol 15 • Issue 1.
9. Randall E Harris, Joanne Beebe, Galal A Alshafie. Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. Journal of Experimental Pharmacology 2012:4 91–96.
10. Laura W. Bowers, Ilane X.F. Maximo, Andrew J. Brenner2, Muralidhar Beeram, Stephen D. Hursting, Ramona S. Price, Rajeshwar R. Tekmal , Christopher A. Jolly , and Linda A. deGraffenrie. NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin– Aromatase Interactions. Therapeutics, Targets, and Chemical Biology, Cancer Res; 74(16) August 15, 2014
11. Brittany K. Mercado, Stephan Dil chert, Casey Giordano & Deniz S. Ones. Counterproductive Work Behaviors. The SAGE Handbook of Industrial, Work, and Organizational Psychology 109-211 © Mercado, Dil chert, Giordano, & Ones 2018.
12. L R Howe, K Subbaramaiah, A M C Brown and A J Dannenberg. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine-Related Cancer (2001) 8 97–114.
13. Gulbostan Yusup , Yasunori Akutsu , Muradil Mutallip , Wei Qi , Xin Hu , Aki Komatsu-Akimoto , Isamu Hoshino , Naoyuki Hanari , Mikito Mori , Naoki Akanuma , Yuka Isozaki, And Hisahiro Matsubara. A Cox-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. International Journal Of Oncology 44: 1146-1152, 2014.
14. Chell, S., Kadi, A., Caroline Williams, A., & Paraskeva, C. (2006). Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochemical et Biophysical Acta (BBA) - Reviews on Cancer, 1766(1), 104–119.
15. Kashfi, K., & Rigas, B. (2005). Non-COX-2 targets and cancer: Expanding the molecular target repertoire of chemoprevention. Biochemical Pharmacology, 70(7), 969–986.
16. Sarah L. Horn, and Ian S. Fentiman. The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer. Pharmaceuticals 2010, 3, 1550-1560.
17. Laura W. Bowers & Linda A. deGraffenried. Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population. Curr Pharmocol Rep (2015) 1:336–345.
18. Friederike hoellen, katharina kelling, christine dittmer, klaus diedrich, michael friedrich and marc thill1. impact of cyclooxygenase-2 in breast cancer, anticancer research 31: 4359- 4368 (2011).
19. Gurpreet Singh-Ranger , Mohamed Salhab , Kefah Mokbel,The role of cyclooxygenase-2 in breast cancer: review, Breast Cancer Res Treat (2008) 109:189–198.
20. Mi?oszRegulski1, KatarzynaRegulska2, Wies?awPruka?a, Carol A. Rouzer and Lawrence J. Marnett1, Cyclooxygenases: structural and functional insights, Published, JLR Papers in Press, October 23, 2008. DOIDOI 10.1194/jlr.R800042 JLR200.
21. Zakir Khan, Noor Khan, Ram P. Tiwari, Nand K. Sah, GBKS Prasad and Prakash S. Bisen. Biology of Cox-2: An Application in Cancer Therapeutics. Current Drug Targets, 2011, 12, 1082-1093.
22. D Mazhar, R Ang and J Waxman. COX inhibitors and breast cancer. British Journal of Cancer (2006) 94, 346–350.
23. Sayyed Mohammad Ismail Mahboubi Rabbani & Afshin Zarghi. Expert Opinion On Therapeutic Patents 2019, Vol. 29, No. 6, 407–427. [fig]
24. Patrignani, P., Tacconelli, S., Sciulli, M. G., & Capone, M. L. (2005). New insights into COX-2 biology and inhibition. Brain Research Reviews, 48(2), 352–359.
25. 2Blake, C., & Kehm, R. (2019). Comparing breast cancer treatments using automatically detected surrogate and clinically relevant outcomes entities from text. Journal of Biomedical Informatics: X, 1, 100005.
26. Nilanjan Ghosh, Rituparna Chaki, Vivekananda Mandal, Subhash C. Mandal. COX-2 as a target for cancer chemotherapy. pharmacological reports 2010,62,233-244.
27. NJ Bundren, and NLP Barnes. Potential use of COX-2–aromatase inhibitor combinations in breast cancer. British Journal of Cancer (2005) 93(SUPPl 1), S10–S15.
28. Pelin Kanten, and Funda Er Ülker. The Effect of Organizational Climate on Counterproductive Behaviors: An Empirical Study on the Employees of Manufacturing Enterprises. The Macrotheme Review 2(4), Summer 2013.
29. Méric, J.-B., Rottey, S., Olaussen, K., Soria, J.-C., Khayat, D., Rixe, O., & Spano, J.-P. (2006). Cyclooxygenase-2 as a target for anticancer drug development. Critical Reviews in Oncology/Hematology, 59(1), 51–64.
30. Volume 3 – 2013.
31. 74(16) August 15, 2014.
32. Singh-Ranger, G., & Mokbel, K. (2002). The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition. European Journal of Surgical Oncology (EJSO), 28(7), 729–737. doi:10.1053/ejso.2002.1329.
33. Emma Gervin  , Bonita Shin  , Reid Opperman , Mackenzie Cullen  , Riley Feser , Sujit Maiti and Mousumi Majumder . Chemically Induced Hypoxia Enhances MiRNA Functions in Breast Cancer. Cancers 2020, 12, 2008.
34. Nageswara Rao, R., Meena, S., & Raghuram Rao, A. (2005). An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices. Journal of Pharmaceutical and Biomedical Analysis, 39(3-4), 349–363.
35. Friederike Hoellen, Katharina Kelling, Christine Dittmer, Klaus iedrich, Michael Friedrich, and MARC THILL. Impact of Cyclooxygenase-2 in Breast Cancer. ANTICANCER RESEARCH 31: 4359-4368 (2011).
36. Ufuk Tan Timur, Marjolein M. J. Caron, Ralph M. Juken, Yvonne M. Bastian's-Jenniskens, Tim J. M. Welting, Lodewijk W. van Rhijn, Gerjo J. V. M. van Osch , and Pieter J. Emans. Chondroprotective Actions of Selective COX-2 Inhibitors In Vivo: A Systematic Review. Int. J. Mol. Sci. 2020, 21, 6962.
37. Sturgeon, S. R., & Ronnenberg, A. G. (2010). Pomegranate and breast cancer: possible mechanisms of prevention. Nutrition Reviews, 68(2), 122–128.
38. Naoki Akanuma, Yuka Isozaki, and HISAHIRO MATSUBARA. A COX-2 inhibitor enhances the antitumor effects of chemotherapy and radiotherapy for esophageal squamous cell carcinoma. INTERNATIONAL Journal Of Oncology 44: 1146-1152, 2014.
39. Chow, L. W.-C., Yip, A. Y.-S., Loo, W. T.-Y., Lam, C.-K., & Toi, M. (2008). Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. The Journal of Steroid Biochemistry.
40. Breast cancer: A review of risk factors and diagnosis Obeagu, Emmanuel Ifeanyi PhD Obeagu, Getrude Uzoma BN Sc Department of Medical Laboratory Science, Kampala International University, Kampala, Uganda School of Nursing Science, Kampala International University, Kampala, Uganda.Received: 29 July 2023 / Received in final form: 15 December 2023 / Accepted: 18 December 2023[ definition 40 to 47]
41. Obeagu EI, Babar Q, Vincent CC, et al. Therapeutic targets in breast cancer signaling: a review. J Pharm Res Int. 2021; 33:82–99.
42. Ibekwe AM, Obeagu EI, Ibekwe CE, et al. Challenges of exclusive breastfeeding among working class women in a teaching hospital South East, Nigeria. J Pharm Res Int. 2022; 34:1.
43. Aizaz M, Khan M, Khan FI, et al. Burden of breast cancer: developing countries perspective. Int J Innov Appl Res. 2023; 11:31–7.
44. Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017; 13:1387–97.
45. Sinha T. Tumors: benign and malignant. Cancer Ther Oncol Int J. 2018; 10:555790.
46. Edward U, Obeagu EI, Okorie HM, et al. Studies of serum calcium, inorganic phosphate, and magnesium levels in lactating mothers in Owerri. J Pharm Res Int. 2021; 33:209–16.
47. Obeagu EI, Ahmed YA, Obeagu GU, et al. Biomarkers of breast cancer: overview. Int J Curr Res Biol Med. 2023; 8:8–16